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Abstract
Available data from observational studies on the association of admission hyperglycaemia 
(aHG) with outcomes of acute ischaemic stroke (AIS) patients treated with intravenous 
thrombolysis (IVT) are contradictory especially when stratified by diabetes mellitus (DM) 
history. We assessed the association of aHG (≥144 mg/dl) with outcomes stratified by DM 
history using propensity score matched (PSM) data from the SITS-ISTR. The primary safety 
outcome was symptomatic intracranial haemorrhage (SICH); three-month functional 
independence (FI;mRS scores 0-2) represented the primary efficacy outcome. Patients with and 
without aHG did not differ in baseline characteristics both in the non-diabetic (n=12,318) and 
diabetic (n=6,572) PSM subgroups. In the non-DM group, patients with aHG had lower 3-
month FI (53.3% vs. 57.9%,p<0.001) rates, higher 3-month mortality rates (19.2% vs. 
16.0%,p<0.001) and similar SICH rates (1.7% vs. 1.8%,p=0.563) compared to patients without 
aHG. Similarly, in the DM group, patients with aHG had lower rates of 3-month favourable 
functional outcome (mRS scores 0-1, 34.1% vs. 39.3%,p<0.001) and FI (48.2% vs. 
52.5%,p<0.001), higher 3-month mortality rates (23.7% vs. 19.9%,p<0.001) and similar SICH 
rates (2.2% vs. 2.7%,p=0.224) compared to patients without aHG. In conclusion, aHG was 
associated with unfavorable 3 month clinical outcomes in both diabetic and non-diabetic AIS 
patients treated with IVT. 
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Text
Introduction
More than a third of acute ischaemic stroke (AIS) patients present with increased 
plasma glucose on hospital admission (1, 2). Hyperglycaemia after AIS has been acknowledged 
as an independent predictor of poor outcome for more than 20 years (3), and more recently  
several observational studies suggested that increased plasma glucose on presentation is also 
an independent predictor for symptomatic intracerebral haemorrhage (SICH) and unfavourable 
clinical outcomes in AIS patients treated with intravenous thrombolysis (IVT) (4-7). 
Interestingly, this association of hyperglycaemia with poor clinical outcomes has also been 
reported in patients with successful recanalization following IVT (8).
However, when stratified by the history of diabetes mellitus (DM) data from 
observational studies on the association of hyperglycaemia with IVT outcomes yields 
contradictory findings. In the Canadian Alteplase for Stroke Effectiveness Study (CASES) 
admission hyperglycaemia (>144 mg/dl) was independently associated with poor outcomes 
following IVT administration in both diabetic and non-diabetic patients (9), while in the Safe 
Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-
ISTR) admission hyperglycaemia was only associated with a higher risk of SICH and mortality  
in patients without a history of diabetes mellitus, but not in diabetic patients (10).
In view of these discrepant findings we sought to assess the association of 
hyperglycaemia with early outcomes of AIS patients treated with IVT, stratified by the history 
of DM, using propensity score matched (PSM) data from the SITS-ISTR registry. 
Methods
We analyzed prospectively collected data from the SITS-ISTR registry from 
participating centers treating AIS patients with IVT using the IVT register platform, as 
previously described (11). We included all IVT-treated AIS patients registered in the SITS-
ISTR standard dataset between January 2010 and December 2017 if they had available data 
regarding: 1. the history of diabetes mellitus, 2. baseline plasma glucose values, 3. disability 
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prior to stroke onset [modified Rankin Scale (mRS) scores more than 1], 4. three-month 
functional outcome assessment using the mRS-score. Patients who have had endovascular 
treatment, alone or following administration of tissue plasminongen activator (tPA), were 
excluded from the present analysis. We also excluded patients enrolled in the SITS-ISTR 
register before January 2010, since data of these patients have been included in a previous 
studies investigating the association of admission hyperglycaemia with outcomes in AIS 
patients treated with IVT (10).
The primary safety outcome was the difference in SICH rates according to the SITS-
MOST definition (local or remote parenchymal haemorrhage type 2 on 22–36 hours post-IVT 
imaging scans combined with NIHSS-score increase ≥4 points or leading to death within 24 
hours) (12), while the primary efficacy outcome was the difference in functional independence 
(FI) rates at 3 months (defined as mRS scores 0-2) between patients with and without 
hyperglycaemia on hospital admission. Secondary outcome events of interest included:  1. 
mortality rates at 3 months, 2. favourable functional outcome (FFO) rates at 3 months (defined 
as mRS scores of 0 or 1), 3. SICH rates according to the ECASS II definition (any intracranial 
bleed with ≥4 points worsening on the NIHSS score) (13), 4. rates of any parenchymal 
haemorrhage (PH),  5. the distribution of the 3-month mRS scores (functional improvement) 
between patients with and without hyperglycaemia on hospital admission. All outcomes were 
evaluated separately for diabetic and non-diabetic patients, and all analyses were performed in 
both the unmatched and PSM populations.
Statistical analyses
After dichotomization according to the history of diabetes mellitus and the presence of 
admission hyperglycaemia (≥144 mg/dl) prior to tissue plasminogen activator (tPA) bolus (14), 
patients in the active group (presence of admission hyperglycaemia) were matched to control 
group patients (absence of admission hyperglycaemia) using a structured, iterative propensity 
score model with the primary objective to maximize the balance in the distribution of possible 
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confounders between the two aforementioned groups. The PSM was performed separately for 
diabetic and non-diabetic patients. In the PSM algorithm we included all baseline 
characteristics except for the history of diabetes mellitus and admission hyperglycaemia. The 
corresponding propensity score of the admission hyperglycaemia variable was then calculated 
for each subject and a nearest neighbor matching algorithm was then used to match patients 
with admission hyperglycaemia to patients in the control group (patients without admission 
hyperglycaemia) on a 1:1 ratio (with no replacement) within 0.2*SD of the logit of the 
propensity score. The process of PSM has been described in detail in similar analyses of SITS 
registry (15). To determine whether PSM achieved balance in all potential confounders, we 
compared all baseline characteristics of patients with admission hyperglycaemia to their PSM 
counterparts.
Statistical comparisons were performed between the aforementioned PSM groups 
using the χ2-test (or the Fisher’s exact test) and the unpaired t-test (or Mann-Whitney U-test), 
where appropriate. The distributions of the mRS-scores at three months between the PSM 
groups was compared using the Cochran Mantel-Haenszel test. The associations of admission 
hyperglycaemia and diabetes mellitus history with the outcomes of interest were also evaluated 
using univariable and multivariable binary logistic or ordinal logistic regression models. In 
univariable models of all baseline characteristics a threshold of p<0.1 was used to identify 
candidate variables for inclusion in the multivariate regression models that tested statistical 
significance hypothesis at a significance level of 0.05.
All statistical analyses were performed with RStudio: A Language and Environment 
for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria) (16), with 
the use of the “MatchIt” package (Matching software for causal inference) for matching patients 
across the two groups (17), and the Stata Statistical Software Release 13 (College Station, TX, 
StataCorp LP).
Results
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Out of a total 109,324 consecutive AIS patients treated with IVT between January 1, 
2010 and December 30, 2017 we identified 54,206 eligible patients (Figure 1). In the unmatched 
cohort, non-diabetic patients with admission hyperglycaemia were older (p<0.001), more likely 
to be female (p<0.001), with greater neurological severity on admission (p<0.001), a higher 
prevalence of hypertension (p<0.001), hyperlipidemia (p=0.012), atrial fibrillation (p<0.001) 
and congestive heart failure (p<0.001), a lower prevalence of current smoking (p<0.001) and 
previous stroke (p<0.001), higher rates of disability prior to the index event (p=0.006), higher 
systolic blood pressure on admission and longer onset-to-treatment times (p<0.001) compared 
to non-diabetic patients without admission hyperglycaemia. Non-diabetic patients with 
admission hyperglycaemia had lower rates of 3-month FFO (39.3% vs. 46.9%, p<0.001) and 
FI (51.9% vs. 61.3%, p<0.001), higher rates of any PH (5.6% vs. 4.5%, p<0.001) and SICH 
according to the ECASS II definition (5.5% vs. 3.8%, p<0.001), higher 3-month mortality rates 
(2.1% vs. 1.4%, p<0.001) and higher mRS scores at 3-months [2 (1-5) vs. 2 (0-4), p<0.001] 
compared to non-diabetic patients without admission hyperglycaemia. No difference in the 
SITS-MOST SICH rates was detected between the two groups (1.9% vs. 1.6%, p=0.083; eTable 
1, appendix).
In the unmatched cohort of diabetic patients, individuals with admission 
hyperglycaemia were younger (p<0.001), with a lower prevalence of hyperlipidaemia 
(p<0.001) and higher systolic and diastolic blood pressure on admission (p<0.001) compared 
to diabetic patients without admission hyperglycaemia (eTable 1, appendix). Diabetic patients 
with admission hyperglycaemia had lower rates of 3-month FFO (32.7% vs. 37.7%, p<0.001) 
and FI (46.3% vs. 50.6%, p<0.001), higher rates of any PH (7.5% vs. 6.1%, p=0.008) and SICH 
according to the ECASS II definition (7.3% vs. 6.2%, p=0.039), higher 3-month mortality rates 
(2.6% vs. 2.1%, p<0.001) and higher mRS scores at 3-months [3 (1-6) vs. 2 (1-5), p<0.001]. 
There was no difference in the SITS-MOST SICH rates (2.8% vs. 2.3%, p=0.130) between the 
two groups (diabetic patients with and without admission hyperglycaemia).
PSM in non-diabetic patients resulted in two groups of 6,159 patients each (Figure 1), 
balanced for all baseline characteristics (Table 1). Distributions of propensity scores before and 
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after matching are presented in eFigure 1, appendix. Non-diabetic patients with admission 
hyperglycaemia (68% treated within 3 hours from symptom onset) had lower rates of 3-month 
FFO (40.6% vs. 44.2%, p<0.001), lower rates of 3-month FI (53.3% vs. 57.9%, p<0.001) and 
higher rates of 3-month mortality (19.2% vs. 16.0%, p<0.001), as compared to non-diabetic 
patients without admission hyperglycemia. (Figure 2A). We detected no difference in the rates 
of any PH (5.1% vs. 4.6%, p=0.176) and SICH between the two groups according to SITS 
MOST (1.7% vs. 1.8%, p=0.563) and ECASS II definitions (5.0% vs. 4.6%, p=0.307).
Likewise, PSM in diabetic patients resulted in two groups of 3,286 patients each 
(Figure 1), balanced for all baseline characteristics (Table 2). Distributions of propensity scores 
before and after matching are presented in eFigure 2, appendix. Diabetic patients with 
admission hyperglycaemia (65% treated within 3 hours from symptom onset) had lower rates 
of 3-month FFO (34.1% vs. 39.3%, p<0.001), lower rates of 3-month FI (48.2% vs. 52.5%, 
p<0.001) and higher rates of 3-month mortality (23.7% vs. 19.9%, p<0.001), as compared to 
diabetic patients without admission hyperglycemia. (Figure 2B). There was no difference in the 
rates of any PH (6.4% vs. 6.1%, p=0.551) and SICH according to SITS-MOST (2.2% vs. 2.7%, 
p=0.224) and ECASS II definitions (6.9% vs. 5.8%, p=0.084) between the two groups. 
Both history of diabetes mellitus and admission hyperglycaemia were independently 
(p<0.05) associated with a lower likelihood of 3-month FFO and 3-month FI, higher risk of 3-
month mortality and worse 3-month functional outcomes (shift analysis) on multivariable 
logistic regression analyses of the unmatched cohort after adjustment for potential confounders 
(Table 2 & eTables 2-6, appendix). The risk of SICH was associated with a history of diabetes 
mellitus (OR=1.41, 95%CI: 1.16-1.72, p=0.001) but not with admission hyperglycaemia 
(OR=1.10, 95%CI: 0.92-1.32, p=0.292) in unmatched AIS patients treated with IVT (Table 2 
& eTable 2, appendix). There was no interaction (p>0.1) of the history of diabetes mellitus on 
the association of admission hyperglycaemia with SICH according to the SITS MOST 
definition, 3-month FI, 3-month mortality and 3-month functional improvement in the 
unmatched cohort of AIS patients treated with IVT (eFigure 3, appendix). We detected a 
significant interaction (p=0.032) of the history of diabetes mellitus on the association of 
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admission hyperglycaemia with 3-month FFO (eFigure 3, appendix). More specifically, 
admission hyperglycaemia had a more pronounced adverse impact on FFO in diabetic 
(OR=0.72, 95%CI: 0.65-0.82) than in non-diabetic (OR=0.84, 95%CI: 0.79-0.90) patients.
Finally, increasing admission plasma glucose levels were linearly associated with 
lower odds of 3-month FI (unadjusted analyses, Figure 3A) and of 3-month FFO (unadjusted 
analyses, eFigure 4, appendix) both in diabetic and non-diabetic patients. We also documented 
a linear relationship of increasing admission plasma glucose levels with higher likelihood of 3-
month mortality both in diabetic and non-diabetic patients (Figure 3B). The associations of 
admission plasma glucose levels with outcomes of interest on multivariable logistic regression 
analyses of the unmatched cohort after adjustment for potential confounders are presented in 
eTable 7. Increasing admission plasma glucose levels were associated with higher adjusted 
odds of 3-month mortality, while they were negatively related to the likelihood of 3-month 
FFO, FI and functional improvement. No independent association of admission plasma glucose 
with SICH according to the SITS MOST definition was found.
Discussion
Our study showed that admission hyperglycaemia is associated with unfavourable 
clinical outcomes, including 3-month FFO, FI and functional improvement, in both diabetic 
and non-diabetic AIS patients. These associations were documented both in the unmatched 
cohort following adjustment for potential confounders and in the PSM cohorts of diabetics and 
non-diabetics AIS patients. We documented no relationship of admission hyperglycaemia with 
the risk of SICH in either diabetic or non-diabetic AIS patients. 
Our results are in agreement with the findings of the CASES study (9), confirming 
hyperglycaemia as an independent risk factor for unfavourable outcomes in AIS patients 
receiving IVT treatment, while they are not in accordance to the findings of the previous SITS 
report (10) suggesting potential disparities in the association of admission hyperglycaemia with 
early functional outcomes according to the history of diabetes mellitus. However, it should be 
noted that the difference in findings may be attributed to differences in sample sizes (16.049 
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AIS patients in the previous study (10) vs. 54.206 AIS patients in the current report) and 
statistical analysis plan (PSM vs. multivariable analyses adjusting for confounders). Despite 
the strong association of hyperglycaemia in AIS outcomes, also evident in cases of large vessel 
occlusion treated with mechanical thrombectomy (18, 19), there is currently evidence of 
improved outcomes in AIS with hyperglycaemia and tight glycaemic control in the acute phase, 
in patients treated conservatively (20, 21) or with IVT (22). Moreover, the recently presented 
results from a multicenter, phase III randomized,-controlled clinical trial [The Stroke 
Hyperglycemia Insulin Network Effort (SHINE) Trial] suggest that intensive glucose control 
(between 80mg/dL and 130 mg/dL) with IV insulin administration in AIS not only fails to 
improve functional outcomes but is on the contrary associated with a substantially higher risk 
for hypoglycaemia (23). In accordance to the aforementioned findings, both guidelines from 
the European Stroke Organization (ESO) and American Heart Association/ American Stroke 
Association (AHA/ASA) recommend against the tight treatment of hyperglycaemia in AIS and 
suggest moderate glycemic control in the range of 140-180 mg/dl (24, 25). In the latest 
guideline of the American Diabetes Association for inhospital management for critically ill 
patients it is advised that iv or sc insulin should be used to manage persistent hyperglycemia 
starting at a cut-off point of 180 mg/dL (10.0 mmol/L). The recommended target glucose range 
for the majority of critically ill patients should be 140–180 mg/dL (7.8–10.0 mmol/L) (26).
Hyperglycaemia during the acute phase of stroke may indicate patients with abnormal 
glucose metabolism, who are known to have an increased risk for adverse cardiovascular 
outcomes (27). Hyperglycaemia is also known to enhance glucose and energy delivery to the 
ischaemic tissue at the cost of exacerbation of cell injury through multiple mechanisms, 
including lactic acidosis and oxidative stress (28). Experimental models suggest that 
hyperglycaemia following ischaemia results in blood-brain barrier dysfunction through an 
increase in oxidative stress and matrix metalloproteinase-9 activity (29). Post-ischaemic 
hyperglycaemia has also been associated with exacerbation of ischaemic neuronal damage 
mediated by transporter signalling (30, 31), in both normal animals and animals with metabolic 
syndrome (32), and with ineffective collateral circulation due to impaired cerebrovascular 
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reactivity (33). Interestingly, in a small cohort increased blood glucose was associated with 
greater acute-subacute lactate production and reduced salvage of brain tissue only in AIS 
patients with perfusion-diffusion mismatch, and not in AIS patients without evidence of viable 
penumbra on neuroimaging (34).
Baseline plasma glucose prior to IVT administration has been incorporated in the 
available prediction scores for post-IVT SICH, namely the SITS SICH score (35), the 
haemorrhage after thrombolysis (HAT) score (36), the SEDAN score (37) and the STARTING-
SICH score (38). However, in a retrospective cohort study of 1,112 IVT-treated consecutive 
AIS patients not only baseline plasma glucose, but also glycated hemoglobin (HbA1c) was 
highlighted as an important predictor of SICH risk following IVT administration, suggesting 
that the association between increased plasma glucose and sICH risk may be a consequence of 
long-term vascular injury attributed to diabetes mellitus rather than the sole result of acute 
hyperglycaemia (39).
Compared to previous reports our study included significantly higher numbers of both 
diabetic and non-diabetic patients, incorporating also AIS patients more than 80 years of age 
and with IVT administration beyond 3 hours. Additionally, we are the first to provide PSM 
analyses on the association of baseline plasma glucose with outcomes separately for diabetic 
and non-diabetic patients. Despite these strengths, some limitations of the current report also 
need to be acknowledged. First, selection and reporting biases cannot be excluded in this 
retrospective analysis of prospectively collected data from a multinational registry with self-
reported safety and effectiveness outcomes and no central adjudication of imaging and clinical 
outcomes. It should also be noted that the history of diabetes mellitus was recorded according 
to the relevant information provided in the registry, while glycated hemoglobin (HbA1c) values 
were not available. Therefore, the possibility that some patients with either undiagnosed 
diabetes or with unrecorded (in the charts) history of diabetes being falsely allocated to the 
group of non-diabetic subjects cannot be excluded. Secondly, although PSM groups were 
balanced for all available baseline characteristics potential imbalances in unmeasured 
confounders cannot be excluded. More specifically, in diabetic patients we were not able to 
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assess potential drug-class effects of antidiabetic medications on stroke outcomes following 
IVT (40-42). Additionally, information on antidiabetic treatment duration, adherence and long-
term control of diabetes were not available. Likewise, information on the causes of death events 
is unavailable and thus the relative risk of SICH-related mortality between the two groups 
cannot be assessed. However, it should be noted that cerebral edema represents a substantial 
cause of 3-month mortality in SITS registry ranging from 18% to 65% according to cerebral 
edema type (43). Third, it should be noted that the cut-off value of 144 mg/dl (8 mmol/L) in 
admission glucose for the definition of hyperglycemia was used for comparability to other 
studies (3, 8, 9, 14). Thus, the optimal threshold for the definition of clinically relevant 
hypeglycemia in AIS patients eligible for IVT treatment remains unknown. Finally, missing 
three month follow-up in a third of total patients and unavailable outcomes of interest in nearly 
half of the whole patient population included in the present registry (Figure 1) may have 
introduced additional bias on the reported associations.
In conclusion, our findings indicate that admission hyperglycaemia is associated with 
unfavourable clinical outcomes in both diabetic and non-diabetic tPA-treated AIS patients in 
adjusted and PSM analyses. We found no significant increase in the risk of SICH in 
hyperglycaemic AIS patients treated with IVT. Future randomized-controlled clinical trials on 
the potential utility of moderate glycaemic control in the population of AIS patients treated with 
IVT that present with hyperglycaemia before tPA-bolus appear to be warranted.
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Table 1. Baseline characteristics and outcomes of matched groups
Variable No Diabetes Mellitus history (n=12,318) Diabetes Mellitus history (n=6,572)
HG+ (n=6,159) HG- (n=6,159) p-value HG+ (n=3,286) HG- (n=3,286) p-value
Age (mean±SD), years 71.5±13.0 71.3±13.2 0.396 72.4±10.3 72.9±10.3 0.097
Males (%) 51.8 52.6 0.387 57.0 56.9 0.980
Admission NIHSS (median, 
IQR)
11 (6-17) 11 (6-17) 0.937 10 (6-16) 10 (6-16) 0.193
Hypertension (%) 67.9 68.5 0.486 85.0 85.5 0.531
Hyperlipidemia (%) 26.5 26.4 0.935 48.3 50.0 0.175
Current smoking (%) 14.8 15.3 0.421 13.0 13.1 0.826
Atrial fibrillation (%) 21.4 21.7 0.661 22.3 22.0 0.744
Congestive heart failure (%) 8.3 8.3 0.974 13.2 13.4 0.856
History of previous stroke* 
(%)
9.9 9.6 0.585 15.7 15.9 0.787
Pre-stroke disability 
(mRS>1, %)
12.3 11.8 0.423 17.4 18.2 0.439
Statin pretreatment (%) 24.8 24.8 0.983 47.0 46.8 0.863
Antiplatelet pretreatment (%) 34.6 34.4 0.865 52.9 53.1 0.902
Anticoagulant pretreatment 
(%)
3.8 4.0 0.578 5.2 4.8 0.461
Admission SBP baseline 
(mean±SD), mmHg
153.2±24.3 152.8±23.7 0.364 157.2±24.2 156.3±24.1 0.115
Admission DBP (mean±SD), 
mmHg
83.0±14.9 83.1±14.8 0.853 82.9±14.8 82.4±14.5 0.212
Admission plasma glucose 
(mean±SD), mg/dL
180.5±40.4 107.9±17.3 <0.001 211.7±62.1 111.9±19.5 <0.001
Onset-to-treatment time 
(mean±SD), min
163.7±65.0 163.3±65.8 0.750 165.6±64.1 166.1±64.8 0.735
SICH (%) – SITS MOST 1.7 1.8 0.563 2.2 2.7 0.224
SICH – ECASS II (%) 5.0 4.6 0.307 6.9 5.8 0.084
Any PH 5.1 4.6 0.176 6.4 6.1 0.551
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FFO (%) 40.6 44.2 <0.001 34.1 39.3 <0.001
FI (%) 53.3 57.9 <0.001 48.2 52.5 <0.001
Mortality at 3-months (%) 19.2 16.0 <0.001 23.7 19.9 <0.001
3-month mRS (median, IQR) 2 (1-4) 2 (1-4) <0.001 3 (1-5) 2 (1-5) <0.001
HG: hyperglycaemia, SD: standard deviation, NIHSS: National Institutes of Health Stroke Scale, IQR: interquartile range, mRS: modified Rankin Scale, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, SICH: symptomatic intracranial haemorrhage, FFO: favorable functional outcome, FI: functional 
independence, PH: parenchymal hemorrhage
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Table 2. Overview of the adjusted analyses on the association of admission hyperglycaemia 
and diabetes mellitus history with outcomes of interest in the unmatched cohort.
OR: odds ratio, cOR: common OR, SICH: symptomatic intracranial haemorrhage, FFO: 
favorable functional outcome, FI: functional independence
Admission hyperglycaemia Diabetes Mellitus
Outcome OR/cOR 
(95%CI)
p-value OR/cOR 
(95%CI)
p-value
SICH (SITS-MOST) 1.10 (0.92, 1.32) 0.292 1.41 (1.16, 1.72) 0.001
3-month FFO 0.82 (0.77, 0.86) <0.001 0.73 (0.68, 0.78) <0.001
3-month FI 0.79 (0.74, 0.83) <0.001 0.71 (0.66, 0.75) <0.001
3-month mortality 1.36 (1.27, 1.46) <0.001 1.52 (1.41, 1.64) <0.001
3-month functional 
improvement
0.82 (0.79, 0.85) <0.001 0.71 (0.68, 0.75) <0.001
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FIGURES
Figure 1. Flowchart presenting the selection of eligible and propensity score matched patients.
Figure 2. Distribution of the modified Rankin Scale scores at three months between (A) 
non-diabetic and (B) diabetic acute ischaemic stroke patients with and without 
hyperglycaemia prior to the administration of intravenous thrombolysis.
Figure 3. Modeled probability of (A) functional independence and (B) mortality at 3-months 
following intravenous thrombolysis treatment by admission blood glucose (unadjusted 
analyses).
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 Figure 1. Flowchart presenting the selection of eligible and propensity score matched patients. 
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 Figure 2. Distribution of the modified Rankin Scale scores at three months between (A) non-diabetic and (B) 
diabetic acute ischaemic stroke patients with and without hyperglycaemia prior to the administration of 
intravenous thrombolysis. 
291x397mm (96 x 96 DPI) 
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 Figure 3. Modeled probability of (A) functional independence and (B) mortality at 3-months following 
intravenous thrombolysis treatment by admission blood glucose (unadjusted analyses). 
291x466mm (96 x 96 DPI) 
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Online Supplemental Materials
eTable 1. Baseline characteristics and outcomes of unmatched groups
Variable No Diabetes Mellitus history (n=43,307) Diabetes Mellitus history (n=10,899)
HG+ (n=9,210) HG- (n=34,097) p-value HG+ (n=5,876) HG- (n=5,023) p-value
Baseline Characteristics
Age (mean±SD), years 71.3±12.8 69.1±14.0 <0.001 72.02±10.4 72.8±10.3 <0.001
Males (%) 51.8 54.7 <0.001 57.0 56.2 0.398
Admission NIHSS (median, 
IQR)
11 (6-17) 10 (6-16) <0.001 10 (6-17) 10 (6-17) 0.374
Hypertension (%) 68.0 62.2 <0.001 86.0 85.7 0.728
Hyperlipidemia (%) 27.0 25.7 0.012 47.7 51.2 <0.001
Current smoking (%) 15.6 18.6 <0.001 13.6 13.9 0.622
Atrial fibrillation (%) 22.3 19.8 <0.001 23.2 22.8 0.581
Congestive heart failure (%) 8.2 7.7 <0.001 13.3 13.5 0.771
History of previous stroke* 
(%)
10.5 11.7 <0.001 15.5 16.5 0.170
Pre-stroke disability 
(mRS>1, %)
12.2 11.2 0.006 17.3 18.3 0.169
Statin pretreatment (%) 24.8 24.7 0.867 46.0 46.3 0.742
Antiplatelet pretreatment (%) 35.2 35.3 0.834 51.4 53.2 0.062
Anticoagulant pretreatment 
(%)
3.9 3.6 0.216 5.6 4.9 0.106
Admission SBP baseline 
(mean±SD), mmHg
153.2±24.0 152.0±23.7 <0.001 158.3±25.1 156.3±24.3 <0.001
Admission DBP (mean±SD), 
mmHg
83.2±14.7 83.0±14.3 0.344 83.6±15.1 82.4±14.5 <0.001
Admission plasma glucose 
(mean±SD), mg/dL
180.1±41.1 107.7±17.3 <0.001 213.0±63.7 111.8±19.6 <0.001
Onset-to-treatment time 
(mean±SD), min
162.7±64.9 158.5±63.2 <0.001 164.8±66.1 163.6±64.8 0.348
Outcomes
Page 26 of 37Diabetes
SICH-SITS MOST (%) 1.9 1.6 0.083 2.8 2.3 0.130
SICH-ECASS II (%) 5.5 3.8 <0.001 7.5 6.1 0.008
Any PH 5.6 4.5 <0.001 7.3 6.2 0.039
FFO (%) 39.3 46.9 <0.001 32.7 37.7 <0.001
FI (%) 51.9 61.3 <0.001 46.3 50.6 <0.001
Mortality at 3-months (%) 2.1 1.4 <0.001 2.6 2.1 <0.001
3-month mRS (median, IQR) 2 (1-5) 2 (0-4) <0.001 3 (1-6) 2 (1-5) <0.001
HG: hyperglycaemia, SD: standard deviation, NIHSS: National Institutes of Health Stroke Scale, IQR: interquartile range, mRS: modified Rankin Scale, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, SICH: symptomatic intracranial haemorrhage, FFO: favorable functional outcome, FI: functional 
independence, PH: parenchymal hemorrhage
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eTable 2. Univariable and multivariable logistic regression analyses on the probability of 
symptomatic intracranial haemorrhage according to the SITS MOST definition.
Baseline characteristic Univariable analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Age 1.04 (1.03, 1.04) <0.001 1.03 (1.02, 1.04) <0.001
Males 1.12 (0.98, 1.29) 0.103 - -
Admission NIHSS 1.04 (1.03, 1.05) <0.001 1.04 (1.03, 1.05) <0.001
Hypertension 1.63 (1.39, 1.91) <0.001 0.98 (0.80, 1.21) 0.881
Diabetes mellitus 1.56 (1.34, 1.82) <0.001 1.41 (1.16, 1.72) 0.001
Hyperlipidemia 1.20 (1.04, 1.38) 0.014 0.84 (0.68, 1.05) 0.123
Current smoking 0.52 (0.41, 0.65) <0.001 0.78 (0.58, 1.05) 0.105
Atrial fibrillation 2.25 (2.14, 2.37) <0.001 1.20 (0.98, 1.46) 0.073
Congestive heart failure 1.33 (1.07, 1.67) <0.001 0.86 (0.65, 1.14) 0.292
History of previous stroke 1.54 (1.29, 1.85) <0.001 1.20 (0.95, 1.51) 0.132
Pre-stroke disability 1.23 (1.01, 1.49) 0.035 0.80 (0.62, 1.00) 0.053
Statin pretreatment 1.42 (1.23, 1.66) <0.001 1.27 (1.02, 1.58) 0.032
Antiplatelet pretreatment 1.89 (1.65, 2.17) <0.001 1.38 (1.15, 1.67) 0.001
Anticoagulant pretreatment 1.33 (0.95, 1.85) 0.098 1.18 (0.79, 1.76) 0.418
Admission SBP baseline 1.11 (1.08, 1.14) <0.001 1.07 (1.02, 1.11) 0.002
Admission DBP 1.08 (1.03, 1.13) 0.002 1.04 (0.97, 1.11) 0.248
Hypeglycaemia on admission* 1.33 (1.15, 1.53) <0.001 1.10 (0.92, 1.32) 0.292
Onset-to-treatment time 1.02 (1.01, 1.03) <0.001 1.02 (1.00, 1.03) 0.008
OR: odds ratio, 95%CI: 95% confidence intervals, NIHSS: National Institutes of Health 
Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood pressure
*≥144 mg/dl vs. <144mg/dl
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eTable 3. Univariable and multivariable logistic regression analyses on the probability of 3-
month favorable functional outcome (mRS-scores of 0-1)
Baseline characteristic Univariable analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Age 0.96 (0.96, 0.96) <0.001 0.97 (0.97, 0.97) <0.001
Males 1.32 (1.28, 1.37) <0.001 1.01 (0.96, 1.07) 0.601
Admission NIHSS 0.85 (0.84, 0.85) <0.001 0.85 (0.84, 0.85) <0.001
Hypertension 0.63 (0.61, 0.66) <0.001 0.91 (0.86, 0.96) 0.001
Diabetes mellitus 0.65 (0.62, 0.68) <0.001 0.73 (0.68, 0.78) <0.001
Hyperlipidemia 0.96 (0.93, 1.00) 0.059 1.19 (1.11, 1.27) <0.001
Current smoking 1.47 (1.41, 1.54) <0.001 0.88 (0.82, 0.94) <0.001
Atrial fibrillation 0.49 (0.47, 0.52) <0.001 0.86 (0.80, 0.92) <0.001
Congestive heart failure 0.49 (0.46, 0.53) <0.001 0.85 (0.77, 0.94) 0.001
History of previous stroke 0.66 (0.62, 0.69) <0.001 0.80 (0.73, 0.86) <0.001
Pre-stroke disability 0.15 (0.14, 0.16) <0.001 0.19 (0.18, 0.22) <0.001
Statin pretreatment 0.87 (0.83, 0.90) <0.001 1.01 (0.94, 1.09) 0.735
Antiplatelet pretreatment 0.70 (0.68, 0.73) <0.001 1.08 (1.02, 1.14) 0.015
Anticoagulant pretreatment 0.58 (0.52, 0.64) <0.001 0.98 (0.85, 1.13) 0.799
Admission SBP baseline 0.96 (0.96, 0.97) <0.001 0.96 (0.95, 0.97) <0.001
Admission DBP 1.01 (1.00, 1.03) <0.001 0.97 (0.96, 0.99) 0.022
Hypeglycaemia on admission* 0.69 (0.66, 0.71) <0.001 0.82 (0.77, 0.86) <0.001
Onset-to-treatment time 0.99 (0.99, 0.99) <0.001 0.98 (0.98, 0.99) <0.001
OR: odds ratio, 95%CI: 95% confidence intervals, NIHSS: National Institutes of Health 
Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood pressure
*≥144 mg/dl vs. <144mg/dl
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eTable 4. Univariable and multivariable logistic regression analyses on the probability of 3-
month functional independence (mRS-scores of 0-2)
Baseline characteristic Univariable analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Age 0.95 (0.95, 0.95) <0.001 0.96 (0.96, 0.97) <0.001
Males 1.39 (1.34, 1.44) <0.001 1.03 (0.98, 1.09) 0.229
Admission NIHSS 0.84 (0.84, 0.84) <0.001 0.84 (0.84, 0.85) <0.001
Hypertension 0.62 (0.60, 0.64) <0.001 0.95 (0.90, 1.01) 0.091
Diabetes mellitus 0.64 (0.61, 0.67) <0.001 0.71 (0.66, 0.75) <0.001
Hyperlipidemia 0.98 (0.95, 1.02) 0.406 - -
Current smoking 1.67 (1.59, 1.75) <0.001 0.95 (0.88, 1.02) 0.155
Atrial fibrillation 0.48 (0.46, 0.50) <0.001 0.90 (0.84, 0.96) 0.001
Congestive heart failure 0.47 (0.45, 0.51) <0.001 0.82 (0.75, 0.90) <0.001
History of previous stroke 0.73 (0.69, 0.77) <0.001 0.90 (0.83, 0.97) 0.010
Pre-stroke disability 0.22 (0.21, 0.23) <0.001 0.31 (0.28, 0.33) <0.001
Statin pretreatment 0.89 (0.86, 0.93) <0.001 1.16 (1.10, 1.24) <0.001
Antiplatelet pretreatment 0.69 (0.67, 0.71) <0.001 1.05 (0.99, 1.11) 0.121
Anticoagulant pretreatment 0.59 (0.54, 0.65) <0.001 0.98 (0.85, 1.12) 0.750
Admission SBP baseline 0.97 (0.96, 0.97) <0.001 0.97 (0.96, 0.97) <0.001
Admission DBP 1.01 (1.01, 1.01) <0.001 0.99 (0.99, 0.99) 0.027
Hypeglycaemia on admission* 0.66 (0.64, 0.69) <0.001 0.79 (0.74, 0.83) <0.001
Onset-to-treatment time 1.00 (0.99, 1.01) 0.202 - -
OR: odds ratio, 95%CI: 95% confidence intervals, NIHSS: National Institutes of Health 
Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood pressure
*≥144 mg/dl vs. <144mg/dl
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eTable 5. Univariable and multivariable logistic regression analyses on the probability of 3-
month mortality.
Baseline characteristic Univariable analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Age 1.07 (1.06, 1.07) <0.001 1.05 (1.05, 1.06) <0.001
Males 0.79 (0.76, 0.82) <0.001 1.25 (1.17, 1.34) <0.001
Admission NIHSS 1.16 (1.15, 1.16) <0.001 1.14 (1.14, 1.15) <0.001
Hypertension 1.72 (1.63, 1.81) <0.001 1.06 (0.98, 1.14) 0.145
Diabetes mellitus 1.68 (1.60, 1.77) <0.001 1.52 (1.41, 1.64) <0.001
Hyperlipidemia 0.99 (0.94, 1.04) 0.717 - -
Current smoking 0.47 (0.44, 0.51) <0.001 0.95 (0.85, 1.06) 0.365
Atrial fibrillation 2.25 (2.14, 2.37) <0.001 1.18 (1.09, 1.27) <0.001
Congestive heart failure 2.54 (2.38, 2.72) <0.001 1.54 (1.39, 1.69) <0.001
History of previous stroke 1.31 (1.23, 1.40) <0.001 1.03 (0.94, 1.14) 0.520
Pre-stroke disability 3.09 (2.92, 3.26) <0.001 1.62 (1.49, 1.76) <0.001
Statin pretreatment 1.11 (1.05, 1.16) <0.001 0.86 (0.80, 0.93) <0.001
Antiplatelet pretreatment 1.54 (1.47, 1.61) <0.001 1.01 (0.94, 1.09) 0.758
Anticoagulant pretreatment 1.96 (1.77, 2.18) <0.001 1.25 (1.08, 1.45) 0.003
Admission SBP 1.02 (1.02, 1.04) <0.001 1.01 (1.00, 1.03) 0.049
Admission DBP 1.00 (0.98, 1.01) 0.421 - -
Hypeglycaemia on admission* 1.68 (1.60, 1.76) <0.001 1.36 (1.27, 1.46) <0.001
Onset-to-treatment time 1.00 (0.99, 1.01) 0.386 - -
OR: odds ratio, 95%CI: 95% confidence intervals, NIHSS: National Institutes of Health 
Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood pressure
*≥144 mg/dl vs. <144mg/dl
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eTable 6. Univariable and multivariable ordinal regression analyses on the probability of 3-
month functional improvement defined as 1-point decrease in 3-month mRS-scores over the 
entire range of score groupings (shift analysis).
Baseline characteristic Univariable analysis Multivariable analysis
cOR (95%CI) p-value cOR (95%CI) p-value
Age 0.95 (0.95, 0.96) <0.001 0.97 (0.97, 0.97) <0.001
Males 1.32 (1.28, 1.35) <0.001 0.96 (0.92, 0.99) 0.038
Admission NIHSS 0.85 (0.85, 0.85) <0.001 0.85 (0.85, 0.86) <0.001
Hypertension 0.62 (0.60, 0.64) <0.001 0.93 (0.90, 0.98) 0.003
Diabetes mellitus 0.63 (0.61, 0.66) <0.001 0.71 (0.68, 0.75) <0.001
Hyperlipidemia 0.96 (0.93, 0.99) 0.014 1.13 (1.07, 1.19) <0.001
Current smoking 1.56 (1.49, 1.61) <0.001 0.91 (0.86, 0.96) <0.001
Atrial fibrillation 0.47 (0.45, 0.49) <0.001 0.86 (0.82, 0.91) <0.001
Congestive heart failure 0.44 (0.42, 0.47) <0.001 0.76 (0.70, 0.81) <0.001
History of previous stroke 0.69 (0.66, 0.72) <0.001 0.83 (0.78, 0.88) <0.001
Pre-stroke disability 0.26 (0.25, 0.27) <0.001 0.39 (0.37, 0.41) <0.001
Statin pretreatment 0.87 (0.84, 0.90) <0.001 1.04 (0.99, 1.10) 0.117
Antiplatelet pretreatment 0.68 (0.66, 0.70) <0.001 1.04 (1.00, 1.10) 0.066
Anticoagulant pretreatment 0.55 (0.51, 0.60) <0.001 0.93 (0.84, 1.03) 0.184
Admission SBP 0.97 (0.96, 0.97) <0.001 0.98 (0.97, 0.99) <0.001
Admission DBP 1.02 (1.01, 1.03) <0.001 0.97 (0.95, 0.98) <0.001
Hypeglycaemia on admission* 0.66 (0.64, 0.68) <0.001 0.82 (0.79, 0.85) <0.001
Onset-to-treatment time 1.00 (1.00, 1.01) 0.052 0.99 (0.98, 0.99) <0.001
cOR: common odds ratio, 95%CI: 95% confidence intervals, NIHSS: National Institutes of 
Health Stroke Scale, SBP: systolic blood pressure, DBP: diastolic blood pressure
*≥144 mg/dl vs. <144mg/dl
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eTable 7. Overview of the adjusted analyses on the association of admission plasma glucose 
levels and diabetes mellitus history with outcomes of interest in the unmatched cohort.
*per 10mg/dl increase
OR: odds ratio, cOR: common OR, SICH: symptomatic intracranial haemorrhage, FFO: 
favorable functional outcome, FI: functional independence
Admission plasma glucose* Diabetes Mellitus
Outcome OR/cOR 
(95%CI)
p-value OR/cOR 
(95%CI)
p-value
SICH (SITS-MOST) 1.01 (0.99, 1.03) 0.065 1.37 (1.12, 1.67) 0.002
3-month FFO 0.97 (0.96, 0.98) <0.001 0.77 (0.72, 0.82) <0.001
3-month FI 0.97 (0.96, 0.98) <0.001 0.75 (0.70, 0.80) <0.001
3-month mortality 1.03 (1.02, 1.04) <0.001 1.46 (1.35, 1.58) <0.001
3-month functional 
improvement
0.97 (0.96, 0.98) <0.001 0.81 (0.75, 0.88) <0.001
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eFigure 1. Distribution of propensity scores for diabetic patients before and after propensity 
score matching. 
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eFigure 2. Distribution of propensity scores for non-diabetic patients before and after 
propensity score matching. 
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eFigure 3. Interaction testing between admission hyperglycaemia and history of diabetes 
mellitus on the outcomes of interest.
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eFigure 4. Modeled probability of favorable functional outcome at 3-months following 
intravenous thrombolysis treatment by admission blood glucose (unadjusted analyses).
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